Our leaders

Determined to solve the intractable

Executive Management Team

Curve Graphic

Jeff Albers

CEO, President and Member of the Board of Directors

Jeff Albers
CEO, President and Member of the Board of Directors

Jeff has more than 25 years of experience working in the biopharmaceutical industry and bringing important new medicines to patients with cancer and rare diseases. In 2014, he joined Blueprint Medicines as Chief Executive Officer and led the research-stage company through an initial public offering. Since that time, Blueprint Medicines has evolved into a leading precision medicine company with a global, fully integrated business, including two FDA-approved therapies and a rapidly advancing pipeline. Jeff previously served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, he held senior commercial and corporate development positions at Genzyme (now a division of Sanofi), including vice president of the U.S. hematology and oncology business unit. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He currently serves on the board of directors at Magenta Therapeutics and the Eastern New England Chapter of the American Cancer Society and is on the board of advisors for Life Sciences Cares. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.

1

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Marion Dorsch, Ph.D.

Chief Scientific Officer

Marion Dorsch, Ph.D.
Chief Scientific Officer

Marion joined Blueprint Medicines from Agios Pharmaceuticals, Inc. where she served as Vice President of Biology. In this role, she was responsible for novel target validation, drug discovery, and biomarker strategy across Agios’ cancer, rare genetic diseases and immuno-oncology portfolios. During her tenure at Agios, Marion contributed to the successful advancement of several molecules targeting defined genetic lesions into clinical trials, including the approval of IDHIFA® (enasidenib), an FDA-approved therapy for adults with relapsed/refractory acute myeloid leukemia (AML) with an IDH2 mutation. Prior to joining Agios, Marion was the Director of Cancer Biology at Sanofi Oncology, where she oversaw drug discovery efforts. Earlier in her career, Marion served as research project leader for sonidegib (Odomzo®), now approved in the U.S. and EU for the treatment of locally advanced basal cell carcinoma, at the Novartis Institutes for Biomedical Research and worked in Inflammation Discovery at Millennium Pharmaceuticals. Marion received her Ph.D. in Biology from the Free University of Berlin, Germany and was a postdoctoral fellow at Columbia University in New York.

3

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Debbie Durso-Bumpus

Chief People Officer

Debbie Durso-Bumpus
Chief People Officer

Debbie is an accomplished human resources executive with a focus on providing strategic direction to companies on people matters, managing rapid growth and creating and maintaining high performance cultures. Most recently, Debbie served as the interim head of human resources for Cubist Pharmaceuticals, Inc., where she was appointed to lead the post-merger human resource integration following the acquisition of Cubist by Merck.  Prior to this role, she was the global senior director for talent management and organizational development at Cubist, where she was primarily responsible for building talent and leadership strength and depth while managing change on a global scale to create a cohesive and highly differentiated culture. Prior to Cubist, Debbie served as the North American manager of talent acquisition and workforce planning at Holcim, Inc., in Waltham, MA. She serves as a member of the board of directors for the Massachusetts Biotechnology Education Foundation, a nonprofit organization committed to supporting science and biotechnology education in Massachusetts through school programs, workforce training and lifelong learning. Debbie earned a B.S. in business management from Bentley University.

4

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Kate Haviland

Chief Operating Officer

Kate Haviland
Chief Operating Officer

Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in business development, commercial and strategic planning, and program management. She has served as a member of the board of directors for Fulcrum Therapeutics since June 2018. Kate previously served as Chief Business Officer of Blueprint Medicines from January 2016 to January 2019. Prior to joining Blueprint Medicines, she served as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals. In this role, she oversaw all aspects of the product development strategy for Idera Pharmaceuticals’ rare disease and oncology pipeline programs, including preclinical research, manufacturing and drug supply, regulatory affairs, clinical development and execution and commercial planning. Prior to joining Idera Pharmaceuticals, Kate was Head of Commercial Development at Sarepta Therapeutics, where she was responsible for product development and commercial planning and for cultivating relationships with key opinion leaders and patient advocacy groups. In addition, Kate previously served as Executive Director of Commercial Development at PTC Therapeutics and held corporate development and project management roles at Genzyme. She holds a B.A. from Wesleyan University with a double major in Biochemistry/Molecular Biology and Economics and an M.B.A. from Harvard Business School.

5

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Christoph Lengauer, Ph.D.

Executive Vice President

Christoph Lengauer, Ph.D.
Executive Vice President

Christoph has a proven record in cancer drug discovery, including contributing to 19 development candidates, 13 drugs or programs that reached first-in-human clinical trials and three approved drugs. He joined Blueprint Medicines from Sanofi, where he was vice president and global head of oncology drug discovery and preclinical development. Before joining Sanofi, Christoph was executive director and senior unit head of oncology discovery at the Novartis Institutes for Biomedical Research (NIBR). Prior to Novartis, Christoph was an associate professor at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine where he worked with Drs. Bert Vogelstein and Ken Kinzler for more than ten years. Christoph discovered that all cancers are genetically unstable and was involved in the identification of several oncogenic driver genes. He has authored more than 100 scientific articles published in top-tier scientific journals, including Cell, Nature and Science. He is a strong and outspoken advocate of patients’ rights and is featured in the New York Times bestseller “The Immortal Life of Henrietta Lacks.” Christoph has received numerous awards, including the Boveri Award in Cancer Genetics, the Benjamin Baker Scholar award, and a V Foundation scholarship.  He was awarded the Novartis Oncology’s President’s Award for top innovator and has been elected to membership in the Johns Hopkins Society of Scholars. Christoph studied human genetics in Salzburg, Austria, and received his Ph.D. from the University of Heidelberg, Germany and his MBA with a focus on medical services management from the Johns Hopkins Carey Business School.

7

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Tracey L. McCain, Esq.

Executive Vice President, Chief Legal and Compliance Officer

Tracey L. McCain, Esq.
Executive Vice President, Chief Legal and Compliance Officer

Tracey is an experienced legal professional with over 20 years of legal, management and transactional experience in the biopharmaceutical industry.  Most recently, Tracey served as senior vice president and head of legal for Sanofi Genzyme, a global business unit of Sanofi, as well as a member of Sanofi Genzyme’s executive leadership team and as a member of the leadership team for Sanofi’s global legal department.  Prior to that, Tracey served as Genzyme’s general counsel after it was acquired by Sanofi in 2011.  In her capacity as Genzyme’s general counsel, Tracey was responsible for all aspects of its legal department in the United States and throughout Europe, including general corporate, commercial and intellectual property matters, and support of business development initiatives.  Prior to Genzyme’s acquisition, Tracey was also responsible for managing the securities and employment law teams and support of non-patent litigation.  Before Genzyme, Tracey was an associate at the law firm Palmer & Dodge LLP. Tracey received her B.A. in political science from the University of Pennsylvania and her J.D. from Columbia University School of Law.

8

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.

Curve Graphic

Fouad Namouni, M.D.

President, Research & Development

Fouad Namouni, M.D.
President, Research & Development

Fouad brings more than 20 years of oncology and cancer immunotherapy drug development expertise, as well as clinical experience as a pediatric oncologist. Prior to joining Blueprint Medicines, Fouad served in leadership roles at Bristol-Myers Squibb (BMS) since 1999, including as the global development lead for the company’s practice-changing cancer immunotherapy franchise. Most recently, he served as Senior Vice President and Head of Oncology Development from August 2016 to April 2020, with responsibility for driving product development plans from early-stage clinical development through commercialization across a portfolio of nearly 30 drug candidates. Previously, he served as Head of Global Medical Affairs overseeing 1,700 employees worldwide from September 2015 to September 2017, and he served as Head of Development at BMS for Opdivo® (nivolumab) and Yervoy® (ipilimumab), immunotherapy medications used in the treatment of cancer, from January 2011 to September 2015. Prior to that, he held roles of increasing responsibility within BMS. Fouad has served as a member of the board of directors of Aprea Therapeutics Inc. since June 2020. He holds an M.D. from the University of Annaba Medical School in Algeria, and a Pediatrics degree from Université Rene Descartes in Paris, France. In addition, he received a Pediatric Oncology and Hematology degree and an M.S. in clinical and experimental pharmacology from Université Paris-Sud in France.

 

Opdivo® and Yervoy® are registered trademarks of Bristol-Myers Squibb Company.

10

Lorem ipsum dolor sit amet, consectetur adipisicing elit. Modi, pariatur nam perspiciatis, voluptatibus illo quae, suscipit dignissimos hic voluptas iusto culpa natus similique cumque sapiente. Dicta at maxime repellat culpa.